China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

WUXI Biologics Cayman will sell a vaccine facility in Ireland to Merck for about US$500 million as the Chinese company seeks ...

China's WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co for about ...

默沙东收购药明生物爱尔兰疫苗资产，是双方在战略调整和全球布局上的重要一步。对于药明生物而言，此次交易不仅能够带来现金流和提升资产效率，还能使其更加专注于核心业务的发展，进一步巩固其在全球疫苗CDMO领域的领先地位。而对于默沙东来说，此次收购将有助于其 ...

WuXi upgraded its WuXiBody platform in bispecific antibody discovery to address the growing global demand for these complex ...

WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...

In Ireland, WuXi Biologics has sold a new vaccines plant to Merck & Co. for €500 million ($521 million). The New Jersey ...

Wuxi Biologics (WXXWY) plans to sell its Irish vaccine facility to Merck (MRK) for around $500M ahead of potential U.S. legislation that would ...

Candid Therapeutics is continuing its mission to flesh out a pipeline of T-cell engagers in record time, signing a ...

近年来，药明生物在可持续发展领域的战略和举措取得了长足进展，并赢得了业界广泛认可。凭借领先的绿色生物药解决方案（Green CRDMO），公司成功入选联合国全球契约组织（UNGC）“‘二十年二十佳’企业可持续发展案例”报告。此外，公司连续两年获得明晟 ...